Literature DB >> 8423907

Ischemic stroke in patients with atrial fibrillation: effect of aspirin according to stroke mechanism. Stroke Prevention in Atrial Fibrillation Investigators.

V T Miller1, J F Rothrock, L A Pearce, W M Feinberg, R G Hart, D C Anderson.   

Abstract

Ischemic strokes occurring in patients with nonrheumatic atrial fibrillation are due to a variety of mechanisms, not exclusively to cardiogenic embolism. Without knowledge of antithrombotic therapy assignment, we categorized strokes in the Stroke Prevention in Atrial Fibrillation Study as presumed cardioembolic or noncardioembolic. We then compared patient clinical and echocardiographic variables, as well as the efficacy of aspirin prophylaxis, for each stroke type. Of 71 ischemic strokes, we categorized 46 (65%) as cardioembolic, 13 (18%) as noncardioembolic, and 12 (17%) as of uncertain cause. Patients developing noncardioembolic strokes, relative to cardioembolic strokes, were more commonly men (p = 0.005) and were more likely to have left ventricular wall motion abnormalities by two-dimensional echocardiography (p = 0.002). Aspirin reduced the occurrence of strokes categorized as noncardioembolic significantly more than it did those categorized as cardioembolic (p = 0.01). These results emphasize the value of considering stroke mechanisms in therapeutic trials of antithrombotic agents and suggest a differential effect of aspirin according to mechanism.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8423907     DOI: 10.1212/wnl.43.1_part_1.32

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  19 in total

Review 1.  Guidelines for stroke prevention in patients with atrial fibrillation.

Authors:  P A Howard
Journal:  Drugs       Date:  1999-12       Impact factor: 9.546

2.  Antiplatelet therapy as a modulator of stroke aetiology: a meta-analysis.

Authors:  Christopher A Rajkumar; Christopher N Floyd; Albert Ferro
Journal:  Br J Clin Pharmacol       Date:  2015-07-02       Impact factor: 4.335

3.  Stroke or left atrial thrombus prediction using antithrombin III and mean platelet volume in patients with nonvalvular atrial fibrillation.

Authors:  Seo-Won Choi; Bo-Bae Kim; Dong-Hyun Choi; Geon Park; Byung Chul Shin; Heesang Song; DongHun Kim; Dong-Min Kim
Journal:  Clin Cardiol       Date:  2017-08-14       Impact factor: 2.882

Review 4.  Atrial fibrillation in heart failure: stroke risk stratification and anticoagulation.

Authors:  JoEllyn M Abraham; Stuart J Connolly
Journal:  Heart Fail Rev       Date:  2014-05       Impact factor: 4.214

Review 5.  Selecting antithrombotic therapy for patients with atrial fibrillation.

Authors:  Christine Tanaka-Esposito; Mina K Chung
Journal:  Cleve Clin J Med       Date:  2015-01       Impact factor: 2.321

Review 6.  New approaches to managing nonvalvular atrial fibrillation: what are the thromboembolic implications?

Authors:  Peter J Kudenchuk
Journal:  J Thromb Thrombolysis       Date:  2015-04       Impact factor: 2.300

7.  Left atrial appendage occlusion and ligation devices: what is available, how to implement them, and how to manage and avoid complications.

Authors:  Arash Aryana; Eduardo B Saad; André d'Avila
Journal:  Curr Treat Options Cardiovasc Med       Date:  2012-10

Review 8.  Alternatives to warfarin for thromboembolism prophylaxis in nonrheumatic atrial fibrillation.

Authors:  Ramin Artang; Humberto Vidaillet
Journal:  J Interv Card Electrophysiol       Date:  2004       Impact factor: 1.900

Review 9.  Percutaneous Left Atrial Appendage Ligation for Stroke Prevention in Atrial Fibrillation.

Authors:  Miguel Valderrábano; Matthew J Price
Journal:  Methodist Debakey Cardiovasc J       Date:  2015 Apr-Jun

10.  Dual Versus Triple Therapy for Atrial Fibrillation After Percutaneous Coronary Intervention: A Systematic Review and Meta-analysis.

Authors:  Safi U Khan; Mohammed Osman; Muhammad U Khan; Muhammad Shahzeb Khan; Di Zhao; Mamas A Mamas; Nazir Savji; Ahmad Al-Abdouh; Rani K Hasan; Erin D Michos
Journal:  Ann Intern Med       Date:  2020-03-17       Impact factor: 25.391

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.